Virus Biomimetic-Delivery Systems for the Production of Vaccines.

The persistent emergence of infectious diseases has underscored the critical demand for next-generation vaccine technologies that are safe, effective, and scalable. This review explores virus biomimetic delivery systems, focusing on virus-like particles (VLPs) and virosomes as promising platforms for vaccine and therapeutic development. VLPs are self-assembled nanostructures composed of viral structural proteins that mimic native virions without carrying genetic material, while virosomes are reconstituted viral envelopes that retain functional glycoproteins but lack a nucleocapsid. Both systems provide strong immunogenicity and safety by mimicking viral architecture while eliminating the risk of replication. The paper examines various expression platforms for VLP production, including bacterial, yeast, insect, mammalian, and plant-based systems, highlighting their respective advantages, challenges, and optimization strategies. Mechanistic insights into antigen presentation, immune activation, and cellular uptake pathways are discussed to explain their superior performance in eliciting humoral and cellular immune responses. Furthermore, current applications of VLPs and virosomes in vaccines against major pathogens such as SARS-CoV-2, influenza, Newcastle disease virus, malaria, hepatitis, and respiratory syncytial virus are reviewed, demonstrating their versatility and clinical potential. By integrating molecular engineering, nanotechnology, and biofabrication strategies, virus biomimetic systems represent a transformative frontier in vaccinology, immunotherapy, and targeted drug delivery.